Equity Profile

NTRA

Natera, Inc.

Health CareBiotechnology$44.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well Natera is expanding its market presence and demand for its genetic testing services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology. With a market cap of $45 billion, Natera plays a significant role in the healthcare sector, leveraging advanced technology to provide insights into genetic conditions and disease risks.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1-2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53. Despite the miss, the stock saw a slight increase of 2.20% the following day.

Management Promises & Guidance

Management emphasized their commitment to expanding their testing capabilities.
They highlighted ongoing research and development efforts aimed at enhancing their product offerings.
Natera plans to focus on increasing market penetration in oncology testing.

Expectations

Wall Street Expectations

Overall, expectations for Natera's upcoming earnings are mixed, given the recent performance and the lack of analyst estimates.

Bull Case

If Natera can demonstrate significant revenue growth and improved testing volumes, it may signal strong demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or shows stagnant growth, it could raise concerns about its long-term viability and lead to a negative response from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected testing volume for the upcoming quarter?

This metric will be crucial in assessing demand for Natera's services and could influence investor confidence.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improvement will be key to evaluating the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Natera's potential for recovery in testing volumes, given the recent focus on genetic testing in healthcare.

Supporting Evidence

Historical data shows that Natera has rebounded from earnings misses in the past.

Options pricing suggests that the market expects a larger move than has been typical for the stock.

Management's commitment to expanding testing capabilities may not be fully reflected in current valuations.

Key Risk

If testing volumes exceed expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect Natera's ability to rebound from prior disappointments and meet market expectations.

Bull Confirmed If

A significant increase in testing volume, exceeding previous quarters, would confirm the bull case.

Bear Confirmed If

Continued earnings misses and stagnant revenue growth would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move of over 14%, indicating that investors expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 1.41%, raising concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on testing volume trends and customer demand.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that may enhance service offerings.
4Insights into R&D advancements and their potential impact on future products.
5Guidance on revenue expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well Natera is expanding its market presence and demand for its genetic testing services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1-2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53. Despite the miss, the stock saw a slight increase of 2.20% the following day.

Management Promises & Guidance

Management emphasized their commitment to expanding their testing capabilities.
They highlighted ongoing research and development efforts aimed at enhancing their product offerings.
Natera plans to focus on increasing market penetration in oncology testing.

Expectations

Wall Street Expectations

Overall, expectations for Natera's upcoming earnings are mixed, given the recent performance and the lack of analyst estimates.

Bull Case

If Natera can demonstrate significant revenue growth and improved testing volumes, it may signal strong demand for its services, leading to a positive market reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or shows stagnant growth, it could raise concerns about its long-term viability and lead to a negative response from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected testing volume for the upcoming quarter?

This metric will be crucial in assessing demand for Natera's services and could influence investor confidence.

How does management plan to address the recent earnings misses?

Understanding management's strategy for improvement will be key to evaluating the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Natera's potential for recovery in testing volumes, given the recent focus on genetic testing in healthcare.

Supporting Evidence

Historical data shows that Natera has rebounded from earnings misses in the past.

Options pricing suggests that the market expects a larger move than has been typical for the stock.

Management's commitment to expanding testing capabilities may not be fully reflected in current valuations.

Key Risk

If testing volumes exceed expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect Natera's ability to rebound from prior disappointments and meet market expectations.

Bull Confirmed If

A significant increase in testing volume, exceeding previous quarters, would confirm the bull case.

Bear Confirmed If

Continued earnings misses and stagnant revenue growth would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move of over 14%, indicating that investors expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further clarity from management.

Miss

A miss could lead to a decline of approximately 1.41%, raising concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on testing volume trends and customer demand.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that may enhance service offerings.
4Insights into R&D advancements and their potential impact on future products.
5Guidance on revenue expectations for the upcoming quarters.